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Accurate and affordable point-of-care diagnostics for tuberculosis (TB) are needed.
Host serum protein signatures have been derived for use in primary care settings,
however validation of these in secondary care settings is lacking. We evaluated
serum protein biomarkers discovered in primary care cohorts from Africa reapplied to
patients from secondary care. In this nested case-control study, concentrations of 22
proteins were quantified in sera from 292 patients from Malawi and South Africa who
presented predominantly to secondary care. Recruitment was based upon intention
of local clinicians to test for TB. The case definition for TB was culture positivity
for Mycobacterium tuberculosis; and for other diseases (OD) a confirmed alternative
diagnosis. Equal numbers of TB and OD patients were selected. Within each group, there
were equal numbers with and without HIV and from each site. Patients were split into
training and test sets for biosignature discovery. A nine-protein signature to distinguish TB
from OD was discovered comprising fibrinogen, alpha-2-macroglobulin, CRP, MMP-9,
transthyretin, complement factor H, IFN-gamma, IP-10, and TNF-alpha. This signature
had an area under the receiver operating characteristic curve in the training set of 90%
(95% CI 86–95%), and, after adjusting the cut-off for increased sensitivity, a sensitivity
and specificity in the test set of 92% (95% CI 80–98%) and 71% (95% CI 56–84%),
respectively. The best single biomarker was complement factor H [area under the receiver
operating characteristic curve 70% (95% CI 64–76%)]. Biosignatures consisting of host
serum proteins may function as point-of-care screening tests for TB in African hospitals.
Complement factor H is identified as a new biomarker for such signatures.
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INTRODUCTION
Tuberculosis (TB) remains a leading cause of death from any
infection worldwide. The number of people accessing treatment
is increasing each year, but in 2019 there were still an estimated
10 million cases and 1.4 million deaths (1). The region with the
highest incidence and fatality rate is Africa, where the prevalence
of HIV co-infection in some areas exceeds 50% (1).
The potential for rapid diagnosis of TB in African hospitals
has been enhanced by the roll-out of the GeneXpert MTB/RIF
test (Xpert, Cepheid, Sunnyvale, California, USA). Xpert is a
sputum-based PCR assay with high sensitivity and specificity (2),
but has several practical limitations. These include high cost,
need for annual overseas calibration, laboratory containment
facilities, and continuous electricity. In addition, as a laboratory-
based assay, Xpert is not a true point-of-care (POC) test that can
deliver a result within a single consultation.
An alternative to pathogen detection is quantification of host-
derived biomarkers, such as serum proteins. Serum proteins
are generally of higher abundance than pathogen products, are
amenable to existing POC technologies such as lateral flow
immunoassay (LFA), and have been shown to discriminate
between different infections when combined as biosignatures (3–
6). In 2016, a cohort study was published by the African European
TB Consortium (AE-TBC) in which a seven-protein signature
was reported that distinguished pulmonary TB from other
respiratory diseases with an area under the receiver operating
characteristic (ROC) curve of 91% (7). The study was conducted
in primary care clinics across five countries in Africa. Participants
presenting with symptoms requiring investigation for TB were
recruited. The seven proteins were selected from a shortlist of 22
that had been discovered in pilot studies.
An accurate, cheap, user-friendly POC test for TB for use in
secondary care hospital settings in sub-Saharan Africa would also
be highly desirable. We therefore retested the signature and all
22 biomarkers from the AE-TBC study in cohorts from a case-
control study that recruited adults presenting with features of TB
to hospitals in Cape Town, South Africa, and Karonga, Malawi,
and a TB clinic in Cape Town (the “ILULU-TB study”) (8). Equal
numbers of patients were recruited with and without HIV to
both TB and other diseases (OD) groups (8). Recruitment of TB
patients at all sites was on the basis of culture positivity. All OD
patients were recruited from hospitals. We therefore considered
this cohort to be reflective of patients presenting to secondary
care. We hypothesised that the seven-protein signature from the
AE-TBC study, or a new signature derived from the same 22
proteins, would distinguish TB from OD in patients from the
ILULU-TB study, regardless of HIV status, with a similar degree
of accuracy as in the AE-TBC study.
METHODS
ILULU-TB Patient Recruitment and
Biobank Sampling
Between 2007 and 2010, 674 adults were recruited to the ILULU-
TB study from Cape Town, South Africa, and Karonga District,
Malawi. These sites have differing prevalences of ODs such
as parasitic infection and differing environmental exposures
(urban vs. rural). Details of recruitment have been described
previously (8). Briefly, patients in the TB and OD groups were
recruited consecutively and based on intention of the local
clinician to test for TB. The criterion for inclusion in the TB
group was at least one positive culture (sputum or tissue) for
Mycobacterium tuberculosis (Mtb), which is the WHO gold
standard (1). Laboratory identification of Mtb was confirmed
by polymerase chain reaction (PCR). All of the TB patients
that were enrolled had pulmonary TB. OD patients had an
established alternative diagnosis, negative cultures for Mtb and
an observed improvement of symptoms after follow-up without
TB treatment. In Cape Town, TB patients were recruited from
either an outpatient clinic (Khayelitsha site B) or hospital sites
(Groote Schuur and GF Jooste), whereas OD patients were all
recruited from the hospital sites. In Karonga, both TB and
OD patients were recruited from Karonga District Hospital. As
healthy controls, adults with latent TB infection (LTBI) were
also recruited. LTBI status was defined by positive tuberculin
skin tests and in-house interferon-gamma release assays in the
absence of TB symptoms (9). Sera were collected from all
participants at recruitment and stored at −80◦C. All groups had
HIV-1 status ascertained.
For the present study, sera from 438 individuals were selected
from the ILULU-TB biobank using random number generation
(Microsoft Excel 2013). Equal numbers were selected for each of
the TB, OD, and LTBI groups. Within each group, equal numbers
were selected with and without HIV, and from each of the two
sites (Table 1). The primary aim was to distinguish TB from OD,
regardless of HIV status or site. The selection process with regard
to the TB and OD patients is illustrated in Figure 1. No sera from
the AE-TBC study were re-analysed as part of this study.
Immunoassays
Luminex assays were used as per the AE-TBC study for
quantification of interleukin-1 receptor antagonist (IL-1RA),
transforming growth factor alpha (TGF-alpha), interferon
gamma (IFN-gamma), IFN-gamma-inducible protein 10 (IP-10),
tumour necrosis factor alpha (TNF-alpha), IFN-alpha-2, vascular
endothelial growth factor (VEGF), matrix metalloproteinase-2
(MMP-2), MMP-9, apolipoprotein A-I (apo-AI), apo-CIII,
transthyretin, complement factor H (complement FH) (Merck
Millipore, Billerica, Massachusetts, USA); and C-reactive
protein (CRP), serum amyloid A (SAA), serum amyloid P
(SAP), fibrinogen, ferritin, tissue plasminogen activator (tPA),
procalcitonin (PCT), haptoglobin, and alpha-2-macroglobulin
(alpha-2-M) (Bio-Rad Laboratories, Hercules, California, USA)
(7). Patients were randomised across the series of assays. Sera
were diluted as per manufacturers’ instructions, except for
MMP-2 and−9 which were diluted 1 in 100, and apo-AI,
apo-CIII, transthyretin and complement FH which were diluted
1 in 30,000 following optimisation. Assays were performed
in single wells with three patients run in duplicate on each
plate to estimate intra-assay variability. Quality controls
were run on each plate. Plates were read on Bio-Plex 200
instruments at Imperial College London with Bio-Plex Manager
v6.1 software (Bio-Rad). Intra-assay variability, calculated
Frontiers in Immunology | www.frontiersin.org 2 February 2021 | Volume 12 | Article 639174
Morris et al. Serum Protein Biomarkers of Tuberculosis
TABLE 1 | Demographic and clinical features for the 438 participants randomly selected from the ILULU-TB cohort for this study.
TB, HIV– TB, HIV+ LTBI, HIV– LTBI, HIV+ OD, HIV– OD, HIV+
CPT Karonga CPT Karonga CPT Karonga CPT Karonga CPT Karonga CPT Karonga



































































These are shown by study site for each of the six clinical groups: active TB (TB), healthy controls with latent TB (LTBI), and unwell patients with other diseases (OD) who initially had TB
in their differential diagnosis. The definition of a TB case was culture positivity for Mycobacterium tuberculosis (Mtb). The definition of an OD case was a confirmed other diagnosis plus
exclusion of TB. HIV+, HIV infected; HIV–, HIV uninfected; CPT, Cape Town; IQR, interquartile range; ART, antiretroviral therapy; BMI, body mass index; n/a, not applicable. Numbers
of missing values were <5 except where indicated by letters a–d (a = 6, b = 5, c = 19, d = 20).
FIGURE 1 | Selection process for inclusion of patients in the biosignature analyses. The flow diagram shows the process from original recruitment to the ILULU-TB
study onwards. TB, tuberculosis; OD, other diseases; HIV−, HIV uninfected; HIV+, HIV infected.
as the mean of the coefficients of variance for each analyte
individually across all plates, was <12% for all proteins. Results
for quality controls fell within expected ranges. If results
were below the lower limit of detection, they were assigned a
value of zero. If above the upper limit, they were retested at a
higher dilution.
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Statistical Analyses
For analyses of individual proteins, all patients with results
for that protein were included. Protein concentrations were
compared between the TB group and each of the OD and
LTBI groups in turn using one-sided Mann-Whitney U-tests.
The performance of each of the 22 proteins to distinguish TB
from each of OD and healthy LTBI in turn by their serum
concentration, regardless of HIV status or site, was assessed by
the area under the respective ROC curve (ROC AUC). Analyses
were performed using GraphPad Prism v7 (GraphPad Software,
La Jolla, California, USA).
For the biosignature analyses, as shown in Figure 1, only
those patients (i.e., TB and OD) for whom data was gathered
for all 22 proteins were included (n = 249). This was because
a finite number of kits were purchased at the outset, hence if
serum from any patient had to be re-tested because a protein
concentration was too high, the total number of patients with
results for that protein was reduced. Healthy LTBI controls were
omitted from these analyses. Patients were classified as TB if the
model predicted the probability of TB was >0.5 (p > 0.5).
To retest the seven-protein signature from the AE-TBC study,
data on the entire AE-TBC cohort were used for discovery
(n = 701) and on this sample of the ILULU-TB cohort for
validation (n = 249). The same method was used as for the
AE-TBC signature [Generalised Discriminant Analyses (GDA)]
using Statistica (Statsoft, Ohio, USA) (7).
For discovery of the optimal new signature, data on the
ILULU-TB cohort alone was used. For consistency with the AE-
TBC study, patients were randomly allocated to training and
test sets at a ratio of 70:30, regardless of HIV status or study
site. The same signature discovery methods were also used,
namely GDA and Random Forest analyses of log-transformed
values. In addition, we also performed variable selection using the
Parallel Regularised Regression Model Search method (PReMS)
on decile-normalised values using “R” v3.2.2 (R Foundation
for Statistical Computing, Vienna, Austria). This is a logistic
regression-based method designed to minimise the number of
biomarkers selected (10). For each method, the same allocation
of patients to training and test sets was used. Assuming the AE-
TBC signature had the same accuracy in our data, we had 95%
power to show a sensitivity of >90% and specificity of >66.5%
with these new signatures.
For a screening test, albeit for community settings, the WHO
recommend a minimum sensitivity of 90% (11). No criteria for a
rule-in test are specified. After obtaining the best new signature
from each method, we therefore re-tested them after adjusting
the cut-off for diagnosis to increase each of the sensitivity and
specificity in turn to 90%. This was to assess the performance of
each signature as either a rule-out or rule-in test for TB. There
were no indeterminate test results.
Ethics Statement
Ethical approval for this study was covered by the approvals for
the ILULU-TB study: the Human Research Ethics Committee of
the University of Cape Town, South Africa (HREC012/2007),
the National Health Sciences Research Committee, Malawi
TABLE 2 | Major clinical diagnoses in the Other Diseases groups of the sample of
the ILULU-TB cohort that was selected for this study.
HIV uninfected HIV infected Total
(% of OD
group)Karonga Cape Town Karonga Cape Town
Pneumonia/
Bronchitis/PCP




3 (8%) 13 (35%) 1 (3%) 2 (5%) 19 (13%)




4 (11%) 0 (0%) 4 (13%) 2 (5%) 10 (7%)
Gastroenteritis/
Hepatitis
0 (0%) 2 (5%) 0 (0%) 6 (15%) 8 (6%)
Kaposi’s Sarcoma 0 (0%) 0 (0%) 1 (3%) 6 (15%) 7 (5%)
Pyelonephritis 0 (0%) 7 (19%) 0 (0%) 0 (0%) 7 (5%)
Cryptococcal
meningitis




0 (0%) 1 (3%) 0 (0%) 4 (10%) 5 (3%)
Bacteraemia (source
not identified)
1 (3%) 0 (0%) 4 (13%) 0 (0%) 5 (3%)
Other** 5 (14%) 0 (0%) 0 (0%) 0 (0%) 5 (3%)
Hepatobiliary disease 0 (0%) 4 (11%) 0 (0%) 0 (0%) 4 (3%)
Peritonitis 3 (8%) 0 (0%) 1 (3%) 0 (0%) 4 (3%)
Malaria 1 (3%) 0 (0%) 1 (3%) 0 (0%) 2 (1%)
IBD 0 (0%) 0 (0%) 0 (0%) 1 (3%) 1 (1%)




0 (0%) 0 (0%) 1 (3%) 0 (0%) 1 (1%)
TOTAL 36 37 32 40 145
Data are stratified by HIV status and site. *Lung cancer (n = 7), lymphoma (n = 3),
dermatological tumour (n = 2), unspecified (n = 2), mesothelioma (n = 1), hepatocellular
carcinoma (n = 1), metastatic adenocarcinoma (n = 1), benign salivary gland tumour (n
= 1). **Epilepsy (n = 3), headache (n = 1), pain unspecified (n = 1). One patient had no
diagnosis listed, hence data is shown for 145 patients.
(NHSRC/447), and the Ethics Committee of the London School
of Hygiene and Tropical Medicine (5212).
RESULTS
Demographic and clinical features of individuals selected for
this study are shown in Table 1. The range of diagnoses that
comprised the OD group is shown in Table 2. Medians and
interquartile ranges of proteins in each group are shown in
Supplementary Table 1.
Performance of Biomarkers Individually
The best performing protein was complement factor H (FH). As
shown in Table 3, this had a ROC AUC of 70% (95% confidence
interval (CI): 64–76%). This performance was preserved across
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Complement FH 292 70 (64–76) 58 (53–62)
IP-10 282 66 (60–73) 82 (79–86)
IFN-gamma 284 66 (60–72) 80 (76–84)
SAA 263 65 (58–71) 83 (80–86)
VEGF 278 64 (57–71) 70 (65–74)
Haptoglobin 263 64 (58–71) 62 (57–66)
SAP 267 64 (57–71) 58 (53–63)
Transthyretin 292 61 (55–68) 78 (74–82)
Apo-CIII 292 58 (51–64) 65 (61–70)
Ferritin 263 57 (50–64) 78 (75–82)
tPA 263 57 (50–64) 72 (68–76)
Alpha-2-M 267 57 (50–64) 54 (49–58)
Fibrinogen 263 56 (49–63) 73 (69–77)
TGF-alpha 284 55 (49–62) 73 (69–77)
TNF-alpha 284 53 (46–59) 69 (65–74)
MMP-9 292 53 (47–60) 59 (53–64)
Apo-AI 292 52 (45–59) 69 (65–73)
Procalcitonin 263 52 (45–59) 68 (63–72)
IFN-alpha-2 284 52 (45–58) 67 (62–71)
MMP-2 292 52 (45–58) 54 (49–59)
CRP 267 51 (43–58) 84 (81–87)
IL-1RA 283 51 (44–58) 63 (58–68)
Areas under the receiver operating characteristic curve (ROC AUCs) for the performance
of each protein in distinguishing TB (n = 146) from OD (n = 146) are shown, regardless of
HIV status or site. Proteins are listed in descending order of performance in the ILULU-TB
cohort with the numbers of patients for which results were obtained for that protein. ROC
AUCs are shown as percentages. Results from the AE-TBC study are shown to the right
for comparison (6). Bracketed values indicate 95% confidence intervals.
the sites (70% in Cape Town, 71% in Karonga) and HIV status
(71% in HIV uninfected, 69% in HIV infected). ROC curves
for these subdivisions are shown in Supplementary Figure 1.
In addition, as shown in Figure 2, in comparison with the
healthy LTBI control group, concentrations were higher in the
TB group but trended toward being lower in the OD group (p
= 0.072). This contrasted with the other 21 proteins, in which
concentrations in the TB and OD groups differed from those in
the LTBI group in the same direction.
The concentrations of the top four individual biomarkers in
each group are shown in Figure 2, and a display of all individual
ROC AUCs is shown in Table 3. In comparison with the AE-
TBC study, four proteins performed better in the ILULU-TB
cohort (complement FH, SAP, haptoglobin, and alpha-2-M).
The remaining 18 showed inferior performance, and the protein
with the largest drop in performance was CRP, which was the
best performing biomarker in the AE-TBC study and part of
the seven-protein signature. Individual ROC AUCs in order of
their difference compared to the AE-TBC study are shown in
Supplementary Figure 2.
The performance of each protein was then stratified by
HIV status. 16 proteins performed better in HIV uninfected
patients: complement FH, IP-10, SAA, VEGF, haptoglobin, SAP,
transthyretin, apo-CIII, ferritin, alpha-2-M, TGF-alpha, TNF-
alpha, MMP-9, apo-AI, PCT, and CRP. Five proteins performed
better in HIV co-infected patients: IFN-gamma, fibrinogen, IFN-
alpha-2, MMP-2, and IL-1RA. Confidence intervals overlapped
for every protein, however (Figure 3).
Finally, while the main aim was to assess performance
of proteins to distinguish TB from OD, we also examined
their performance to distinguish TB from LTBI. The protein
with the highest ROC AUC for this purpose was CRP (92%,
Supplementary Table 2).
Performance of the AE-TBC Signature in
the ILULU-TB Cohort
For the biosignature analyses, 122 TB patients and 127 OD
patients for whom results were available for all 22 proteins were
included. There was an equal distribution of patients across the
clinical groups, sites, and HIV status (Figure 1).
The performance of the seven-protein signature from the
AE-TBC study in the ILULU-TB cohort is shown in Table 4.
With the cut-off for defining a positive test at the default
setting (p > 0.5), the sensitivity was greater than in the AE-
TBC study [98% (95% CI: 94–100%)], but specificity was
markedly reduced [12% (7–19%)]. On comparison of biomarker
concentrations between studies, there were significant differences
in some proteins, especially apo-AI (Supplementary Figure 3).
To understand this, we compared concentrations of apo-AI in
our healthy LTBI controls with published normal concentrations.
Concentrations in our LTBI group were 4-fold lower than those
published (medians 324 vs. 1,180 ug/ml) (12). Concentrations
of apo-CIII, however, which was part of the same multiplexed
panel, matched those published (medians 114 vs. 114 ug/ml)
(13). In addition, concentrations of apo-AI in the AE-TBC TB
cohort were higher than published normal concentrations (2,000
vs. 1,180 ug/ml), even though apo-AI concentrations decrease in
TB (7).
Performance of New Signatures Derived in
the ILULU-TB Cohort
The numbers of patients in each subgroup of the ILULU-TB
cohort that were randomised to each of the train and test sets
are shown in Table 5. The same patients were used for this set
of analyses as for the re-test of the AE-TBC signature (n = 249:
122 TB and 127 OD). The results of the best new signatures
from each of the GDA, Random Forests and PReMS methods
are shown in Tables 6–8. Results are shown with the cut-off at
the default setting, and after increasing each of sensitivity and
specificity in turn to 90%. Positive and negative predictive values
(PPV and NPV) are also shown in each case, based on the equal
sizes of the TB and OD groups in this study.
The GDAmethod yielded a five-protein signature comprising
complement factor H, IP-10, CRP, SAA, and transthyretin. The
ROC AUC in the training set was 84% (Table 6). Sensitivities
and specificities in the test set were 81% and 63% initially, 79%
and 41% after increasing sensitivity, and 58% and 89% after
increasing specificity.
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FIGURE 2 | Serum concentrations of the top four protein biomarkers (panels A–D) by clinical group. Scatter-dot plots show results for each patient in the ILULU-TB
cohort, regardless of HIV status or site. P-values are 1-sided and derived from Mann-Whitney tests. Error bars represent medians and interquartile ranges. IP-10,
IFN-gamma-inducible protein 10; IFN-gamma, interferon-gamma.
The results of the Random Forests analyses, using all 22
proteins, are shown in Table 7. Sensitivities and specificities
in the test set were 73% and 71% initially, 92% and
58% after increasing sensitivity, and 95% and 43% after
increasing specificity.
The PReMS method yielded a nine-protein signature
comprising fibrinogen, alpha-2-M, CRP, MMP-9, transthyretin,
complement FH, IFN-gamma, IP-10, and TNF-alpha. As shown
in Table 8, this had a ROC AUC of 90% in the training set
and 84% in the test set. Sensitivities and specificities in the test
set were 86% and 74% initially, 92% and 71% after increasing
sensitivity, and 75% and 81% after increasing specificity. At the
cut-off for increased sensitivity, PPV and NPV in the test set were
75% and 90%, respectively. The performance in each of the HIV
uninfected and co-infected halves of the test set in terms of ROC
AUC was 84% for HIV uninfected patients (95% CI: 72–97%)
and 86% for co-infected patients (95% CI: 71–100%), regardless
of site. The ROC AUC at each of the two sites was 94% at Cape
Town (95%CI: 86–100%) and 78% at Karonga (95%CI: 63–93%),
regardless of HIV status. The difference between the ROC AUCs
at the two sites was not significant by DeLong’s test, however (p
= 0.069) (14).
DISCUSSION
In the field of host serum proteomics-based TB diagnostics, this
study stands out for several reasons. Firstly, it was conducted in
Africa, where the burden of TB is highest, and included equal
numbers of patients with and without HIV. This is important
because the host response to TB may vary by ethnicity (15, 16),
and is also distinct in the setting of HIV co-infection. Differences
in concentrations of serum proteins between TB patients with
and without HIV co-infection have not been extensively studied,
although concentrations of neopterin and beta-2-microglobulin
have both been found to be significantly higher in TB patients
with HIV than without (17). This may reflect a state of “immune
activation” in HIV-associated TB, which is well-recognised
(18–20). Fundamentally, however, the pathogenesis of TB in
HIV co-infection differs significantly, with impaired granuloma
formation, less pulmonary cavitation and more dissemination
(21–23).With the prevalence of HIV amongst patients presenting
with active TB as high as 50% in some areas of Africa, and the
TB case fatality rate in HIV co-infection being approximately
twice that of HIV uninfected individuals (1), it is essential that
any biosignature for use in such settings be derived from a
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FIGURE 3 | Individual ROC AUCs for each of HIV uninfected and infected halves of this sample of the ILULU-TB cohort. Green bars: distinction of TB, HIV– from OD,
HIV–; yellow bars: TB, HIV+ from OD, HIV+.




ILULU-TB cohort (validation set)
ROC AUC 91 (89–93)
Sensitivity 85 (80–90) 98 (94–100)
Specificity 85 (81–88) 12 (7–19)
PPV 71 (65–76) 52 (45–58)
NPV 93 (90–95) 88 (64–99)
For this analysis, the entire AE-TBC cohort was used as the discovery set (n = 701), and
the whole sample of the ILULU-TB cohort as the validation set (n = 249). Results are
shown with the threshold for defining a case of TB at the default setting (p > 0.5). All
results are given as percentages. PPV, positive predictive value. NPV, negative predictive
value. Bracketed values represent 95% confidence intervals.
representative population. The range of other diseases to be
distinguished from TB is also strongly associated with both
geographical location and HIV prevalence. Previous studies have
derived promising serum protein signatures using techniques
including mass spectrometry, but these were either not set in
Africa or did not include or amalgamate sufficient numbers of
HIV co-infected patients in both TB and OD (or control) groups
(24–29). The two sites in Cape Town and Karonga were also
TABLE 5 | Numbers of patients in the ILULU-TB cohort allocated to train and test
sets, for novel biosignature discovery.
Site Clinical group Train (70%) Test (30%) TOTAL
Karonga TB, HIV– 29 3 32
TB, HIV+ 14 17 31
OD, HIV– 11 20 31
OD, HIV+ 24 4 28
Cape Town TB, HIV– 21 9 30
TB, HIV+ 21 8 29
OD, HIV– 27 4 31
OD, HIV+ 27 10 37
TOTAL 174 75 249
Numbers in each of the clinical subgroups and at each study site are shown. Patients
were allocated to train or test set at random. Only those patients with results for all 22
proteins were included.
selected in this study to represent the spread of epidemiological
settings in Africa. Cape Town was selected to represent urban
sites, and also had a low prevalence of malaria. Karonga was
selected as a rural site, and had a high prevalence of malaria and
other parasitic infections. The secondmajor strength of this study
was that patients were prospectively recruited from a point of
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TABLE 6 | Performance of a new five-protein signature derived from Generalised
Discriminant Analyses (GDA).
Training set Test set
ROC AUC 84 (78–90)
Sensitivity 82 (73–90) 81 (65–92)
Specificity 74 (64–83) 63 (46–78)
PPV 75 (65–84) 68 (52–81)
NPV 81 (71–89) 77 (59–90)
After adjustment of cut-off for increased sensitivity
Sensitivity 89 (80–94) 79 (63–90)
Specificity 48 (37–59) 41 (25–58)
PPV 64 (55–73) 58 (43–71)
NPV 80 (67–90) 65 (43–84)
After adjustment of cut-off for increased specificity
Sensitivity 61 (50–71) 58 (41–74)
Specificity 91 (82–96) 89 (75–97)
PPV 87 (76–94) 85 (65–96)
NPV 69 (59–77) 67 (52–80)
This analysis was performed using data on the ILULU-TB cohort only (n = 249). Patients
were randomly assigned to training and test sets at a ratio of 70:30. The signature
comprised Complement FH, IP-10, CRP, SAA, and Transthyretin. Results are shown both
before and after adjusting the probability threshold in the training set for diagnosing TB to
increase each of sensitivity and specificity in turn to 90%.
differential diagnosis. An early study by Agranoff et al. included
African sera, but the OD group comprised a selection of diseases
whose clinical features “can overlap with” those of TB (26). This
is less rigorous, since a population which is more homogenous
clinically (such as ours) is likely to be more homogenous in their
serum proteomes, and therefore a more challenging one from
which to derive markers of host response that are TB-specific.
Thirdly, our signatures were tested using immunocapture.Whilst
not arising from an untargeted proteomic approach, this ensured
that any such signatures were more easily translatable to lateral
flow immunoassay. To our knowledge, none of the relevant mass
spectrometry-based studies published in the literature performed
full technical validation by immunocapture (24–28). Fourthly,
the patients recruited to this study were largely hospital attendees,
which is also a population currently under-represented in the
literature. Two studies recruited hospital patients from sites
including in Africa, but either did not include HIV co-infected
patients in the discovery cohort, or had a low number of HIV
infected patients in the OD group (25, 26). Several recent studies
have employed immunocapture to discover new signatures
including in patients from Africa, but recruitment was limited to
primary care settings (29–33). Patients presenting to hospitals are
likely to be more unwell than those presenting to primary care
settings, and therefore to have a greater degree of disturbance
to their serum proteome. The TB patients in Cape Town were
recruited from a clinic, however all were culture positive as per
the study design, and therefore likely to have had more advanced
disease than cohorts that included clinical diagnoses. Severity
of TB is known to affect the concentrations of serum proteins,
including CRP, procalcitonin, and serum amyloid A, hence the
TABLE 7 | Performance of a new 22-protein signature derived from Random
Forests analyses.
Training set Test set
Sensitivity 72 (61–81) 73 (56–86)
Specificity 80 (70–88) 71 (54–85)
PPV 77 (66–86) 71 (54–85)
NPV 75 (65–83) 73 (56–86)
After adjustment of cut-off for increased sensitivity
Sensitivity 82 (73–90) 92 (78–98)
Specificity 64 (53–74) 58 (41–74)
PPV 69 (59–77) 68 (53–80)
NPV 79 (68–88) 88 (69–97)
After adjustment of cut-off for increased specificity
Sensitivity 65 (54–75) 43 (27–61)
Specificity 89 (80–94) 95 (82–99)
PPV 85 (74–92) 89 (65–99)
NPV 72 (63–81) 63 (49–76)
This analysis was performed using data on the ILULU-TB cohort only (n = 249). The
same patients with the same allocations to training and test sets were used as for the
GDA analyses (Table 4).
TABLE 8 | Performance of a nine-protein signature derived from Parallel
Regularised Regression Model Search.
Training set Test set
ROC AUC 90 (86–95) 84 (73–94)
Sensitivity 83 (75–90) 86 (73–95)
Specificity 82 (73–89) 74 (58–86)
PPV 84 (75–91) 85 (70–94)
NPV 82 (73–89) 76 (62–87)
After adjustment of cut-off for increased sensitivity
Sensitivity 90 (83–95) 92 (80–98)
Specificity 71 (61–80) 71 (56–84)
PPV 75 (66–82) 75 (62–86)
NPV 89 (80–95) 90 (76–97)
After adjustment of cut-off for increased specificity
Sensitivity 73 (63–82) 75 (60–87)
Specificity 90 (82–95) 81 (67–91)
PPV 87 (78–94) 80 (65–91)
NPV 78 (69–85) 77 (63–88)
This analysis was performed using data on the ILULU-TB cohort only (n = 249).
The same patients and allocations were used as for the GDA and Random Forests
analyses (Tables 4, 5). This signature comprised fibrinogen, alpha-2-M, CRP, MMP-9,
transthyretin, complement FH, IFN-gamma, IP-10, and TNF-alpha.
importance of evaluating biomarker performance at this different
level of the healthcare system (34, 35). Other strengths of the
study design were that diagnoses were confirmed in all patients,
and that healthy controls with LTBI infection were included
for reference.
The design of this study was also well-suited to re-testing
the biomarkers from the AE-TBC study. The countries in which
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recruitment took place were a subset of the countries in the AE-
TBC study (Malawi and South Africa); the assays were performed
using the same Luminex kits and analyser; and the same statistical
methods were applied to the data, by the same statistician (7).
To complement the signature discovery process, an additional
method (PReMS) was also used.
Limitations included the fact that even though the recruitment
process was open to extrapulmonary TB (EPTB) cases, no cases
of culture positive TB without pulmonary involvement were
included. In addition, none of the OD cases were documented
as having non-tuberculous mycobacterial disease (NTM), which
may more closely resemble TB in terms of host response (36).
Secondly, this study was limited to the 22 proteins that had
been selected by the AE-TBC based on previous performance in
primary care settings. This was a strength in that the biomarkers
had been through prior selection to diagnose the disease of
interest (TB), but a weakness since they had not all previously
been selected from presentations to secondary care. A third
weakness was that, in terms of the comparison of biomarker
performance between the ILULU-TB and AE-TBC studies, the
study designs were different: ILULU-TB was case-control, with
group sizes held equal, whereas AE-TBC was a cohort study. The
group sizes in the latter therefore reflected local epidemiology,
including with regards to HIV prevalence. Another difference
was that our OD group comprised both pulmonary and non-
pulmonary diseases, whereas AE-TBC focussed on lung diseases
only. A final limitation was that our study did not include an
external cohort in which to validate any new signatures.
Overall, the performance of the proteins individually was
less good in the ILULU-TB cohort, except for complement FH,
SAP, haptoglobin, and alpha-2-M. The results for complement
FH were particularly promising in that diagnostic performance
was sustained across site and HIV status. In addition, the
fact that concentrations of complement FH in the TB and
OD groups moved in a different direction from each other
relative to the healthy controls implies that rising concentrations
of complement FH may be TB-specific. Complement FH did
distinguish TB from OD (or “no-PTB”) in the AE-TBC study,
with higher concentrations in the TB group, but this difference
was more pronounced in the ILULU-TB cohort. A possible
reason for that might be that transcription of complement FH
in vitro is driven by IFN-gamma (37, 38), which in turn has
a central role in the host response in TB (39, 40). In keeping
with this, IFN-gamma serum concentrations were higher in our
TB group than OD group (Figure 2C). As discussed above, the
TB cases in the ILULU-TB study were likely more advanced
than those in the AE-TBC study, which may have driven
serum FH concentrations up higher. An additional possibility
is that FH concentrations were lower in our OD group, again
due to more severe illnesses. Complement FH concentrations
in serum/plasma have not been extensively studied in other
infections, but are known to decrease in inflammatory conditions
such as lupus nephritis and myaesthenia gravis as a result
of excessive complement consumption (41, 42). Enhanced
complement activation and consumption has also been shown
to occur in HIV-infected patients with sepsis (43), and this
may have been relevant for a proportion of our OD cohort.
By contrast, the particularly poor performance of CRP in this
study is interesting, since this was the best-performing biomarker
individually in the AE-TBC study, with concentrations being
higher in the TB group. Whilst concentrations trended toward
being higher in the TB group in the ILULU-TB study, this
difference was not statistically significant, and CRP did not
function as a standalone biomarker. This was likely reflective,
again, of the more severely ill state of the OD patients in
the ILULU-TB cohort, rather than any reduction of levels
in our TB cohort. This is supported by CRP being the top
individual biomarker to distinguish TB from LTBI in our
cohort, and also by previous observations that CRP performs
significantly less well in hospital than in community settings
(44, 45).
The application of the 7-protein signature from the AE-
TBC study directly to the data from the ILULU-TB study was
hampered by the fact that concentrations of some of the proteins
differed significantly between the two studies. Data accuracy and
precision within each of the two studies was good, which suggests
that the commonly observed phenomenon of lot-lot variation
between multiplexed kits was the main contributor (46). It is
possible that the marked decrease in concentrations of apo-
AI in our study represent over-correction of calibration by the
manufacturer of previously high concentrations, such as were
reported in the AE-TBC study.
The newly derived 5-protein GDA signature had a moderately
high ROC AUC in the training set of 84% (78–90%). In the test
set, however, sensitivity and specificity were less promising. The
five proteins were a subset of the seven that comprised the AE-
TBC signature, however, which validates them as being among
the best biomarkers for TB diagnosis. The Random Forests
method produced performances in the test set that were slightly
greater, but this was with all 22 proteins included in the model,
which is less feasible for translation to a POC test.
The best performing test emerged from the PReMS method
in the form of a nine-protein signature comprising fibrinogen,
alpha-2-M, CRP, MMP-9, transthyretin, complement factor H,
IFN-gamma, IP-10, and TNF-alpha. The highest combined
results came from optimising the sensitivity, which yielded
92% sensitivity and 71% specificity in the test set. This was
comparable with the performance of the seven-protein signature
in the AE-TBC study. It also exceeded the WHO minimum
requirements for a “triage test” for TB, which is notable, even
though that particular target was designed with community
settings in mind (11). The potential benefit of a screening test
in hospital settings is clear, since it would decrease the number
of sputum-based investigations that would be needed, including
by GeneXpert, as well as unnecessary courses of TB treatment.
The performance of the signature was unaffected by HIV status,
which is promising for use in African settings, and also contrasts
with the performance of sputum smear microscopy, which is
significantly less sensitive in HIV co-infected patients (47).
This study focussed on culture positive TB, in order to derive
a signature based on confirmed cases. Future validation studies,
however, should include culture negative pulmonary TB cases,
as well as EPTB, and OD groups including NTM disease. In
addition, translation to POC will depend on the availability of
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LFA platforms for measuring multiple proteins. LFAs have been
shown to be feasible for use in sub-Saharan African settings
and accurate across four orders of magnitude, without the need
for a cold chain for distribution or storage (6). Multiplexing
technology is also emerging for LFAs, with multiple proteins
either being detected in series, along one strip (48, 49), or in
parallel, with multiple strips contained within one handheld
device (50).
In summary, we retested the performance of 22 host serum
protein biomarkers of TB that had originally been selected
from primary care studies in Africa in a large sample from a
well-characterised cohort recruited largely from hospitals. The
top-performing single biomarker was complement factor H,
which is a novel marker of TB in this setting. A nine-protein
biosignature was discovered which showed promise for use
as a POC screening test in hospital settings, and performed
equally well in individuals co-infected with HIV. Translation to
this will depend on validation in independent cohorts and on
development of accurate POC platforms.
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